BioSpace News Archive

As part of the Semiconductor Research Corporation (SRC) being selected by NIST’s Advanced Manufacturing Office to define the future of Microelectronics and Advanced Packaging Technology (MAPT), Cardea Bio has been invited as a commercial semiconductor company to share their experience with integrating biology with electronics.

Eli Lilly and Company (NYSE: LLY) will attend Citi’s 17th Annual BioPharma Conference on Wednesday, Sept. 7 , 2022. Daniel Skovronsky, M.D., Ph.D., Lilly’s chief scientific and medical officer, and president of Lilly Research Laboratories, will participate in a fireside chat at 3:30 p.m., Eastern time.

Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will provide an update on its Phase 1 SURPASS trial data and outline future plans for the SURPASS family of trials during a live virtual event to be held on Friday, September 9th, at 8 a.m. EDT (1 p.m. BST).

The global Autologous Cell Therapy Product market is forecast to reach USD 35.64 Billion by 2027, according to a new report by Reports and Data.

The global biobanks market is expected to reach USD 83.82 billion by 2028, according to a new report by Reports and Data.

The global Crohn’s disease drug market is forecast to reach USD 13.72 Billion by 2027, according to a new report by Reports and Data.

Lytix Biopharma, a Norwegian immune-oncology company, releases its second quarter and first half 2022 results - New encouraging clinical data.

Particularly strong performance of Injectable Aesthetics and Dermo-cosmetics product categories with growth of 32% and 31% on a constant currency basis, respectively.

Genexine, announced that late-breaking results from the Phase 2 clinical trial study of its therapeutic DNA vaccine GX-188E in combination with MSD’s anti-PD-1 therapy, KEYTRUDA®, were selected for an oral presentation at the 2022 European Society for Medical Oncology Congress which is being held from September 9-13 in Paris, France.

Alvotech, a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced the initiation of a confirmatory patient study for AVT03, a biosimilar candidate to Prolia® and Xgeva®.